Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Shanghai Spark Pharmaceutical Co. Ltd. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 2 examiners and 2 art units, so the profile reflects separate examination channels.
JACKSON, SHAWQUIA is the busiest listed examiner, with 1 pending matter. Counsel should track each matter independently while comparing claim language and technical positions for consistency across the pharmaceutical portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18920055 | Pharmaceutical Application of Dimyricetin-yl-diselenide in Atherosclerosis | JACKSON, SHAWQUIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18910390 | PHARMACEUTICAL APPLICATION OF DIMYRICETIN-YL-DISELENIDE IN TUMORS | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18920055 | Pharmaceutical Application of Dimyricetin-yl-diselenide in Atherosclerosis | JACKSON, SHAWQUIA | 1626 | §102§112 | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18910390 | PHARMACEUTICAL APPLICATION OF DIMYRICETIN-YL-DISELENIDE IN TUMORS | SOROUSH, LAYLA | 1622 | §102 | Non-Final OA | — | Pending | Oct 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Spark Pharmaceutical Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Shawquia Jackson has the most, with 1 of Shanghai Spark Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
